Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects
International Journal of Molecular Sciences · 27.02.2023 · 24 (5) · 4615
DOI: 10.3390/ijms24054615 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.02.2023. Verfasst von Matteo Ferro und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 244 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Renal cancer management is challenging from diagnosis to treatment and follow-up. In cases of small renal masses and cystic lesions the differential diagnosis of benign or malignant tissues has potential pitfalls when imaging or even renal biopsy is applied. The recent artificial intelligence, imaging techniques, and genomics advancements have the ability to help clinicians set the stratification risk, treatment selection, follow-up strategy, and prognosis of the disease. The combination of radiomics features and genomics data has achieved good results but is currently limited by the retrospective design and the small number of patients included in clinical trials. The road ahead for radiogenomics is open to new, well-designed prospective studies, with large cohorts of patients required to validate previously obtained results and enter clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy.
- Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio, University of Chieti, 66100 Chieti, Italy.
- Urology Unit, SS. Annunziata Hospital, 66100 Chieti, Italy.
- Department of Urology, ASL Abruzzo 2, 66100 Chieti, Italy.
- Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, University of Rome, 00161 Rome, Italy.
ORCID-Profile: Matteo Ferro, Michele Marchioni, Martina Maggi, Francesco Del Giudice, Biagio Barone, Felice Crocetto, Gian Maria Busetto, Daniela Terracciano, Giuseppe Lucarelli, Octavian Sabin Tataru
Zitieren
APA
Ferro, M., Musi, G., Marchioni, M., Maggi, M., Veccia, A., Del Giudice, F., Barone, B., Crocetto, F., Lasorsa, F., Antonelli, A., Schips, L., Autorino, R., Busetto, G. M., Terracciano, D., Lucarelli, G., & Tataru, O. S. (2023). Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects. International Journal of Molecular Sciences, 24(5), 4615. https://doi.org/10.3390/ijms24054615
Vancouver
Ferro M, Musi G, Marchioni M, Maggi M, Veccia A, Del Giudice F, et al. Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects. International Journal of Molecular Sciences. 2023;24(5):4615. doi:10.3390/ijms24054615
BibTeX
@article{Ferro2023,
author = {Ferro, Matteo and Musi, Gennaro and Marchioni, Michele and Maggi, Martina and Veccia, Alessandro and Del Giudice, Francesco and Barone, Biagio and Crocetto, Felice and Lasorsa, Francesco and Antonelli, Alessandro and Schips, Luigi and Autorino, Riccardo and Busetto, Gian Maria and Terracciano, Daniela and Lucarelli, Giuseppe and Tataru, Octavian Sabin},
title = {Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {5},
pages = {4615},
doi = {10.3390/ijms24054615}
}
EUVIMED